Inhibition of phospholipase A2 (PLA2) activity by nifedipine and nisoldipine is independent of their calcium-channel-blocking activity

The effects of several calcium antagonists on phospholipase A₂ (PLA₂) activity were examined. Nifedipine and nisoldipine inhibited a cell-free preparation of PLA₂ in a dose-dependent manner with maximal inhibition of 71–77% observed at 100M. More potent or equipotent dihydropyridine calcium antagonists such as nitrendipine and felodipine did not inhibit PLA₂ activity. In addition, nondihydropyridine calcium antagonists such as diltiazem, verapamil, and cinnarazine failed to reduce PLA₂ activity markedly. Nifedipine and nisoldipine also reduced PLA₂ activity in intact mouse peritoneal macrophages where PLA₂ activity was monitored by free [¹⁴C]arachidonic acid release from [¹⁴C]arachidonic acid-prelabeled cells. When levels of PGE₂ and LTC₄ were measured by radioimmunoassay, it was found that the synthesis of these two metabolites was concomitantly inhibited by nifedipine and nisoldipine. In vivo, nifedipine and nisoldipine inhibited tetradecanoylphorbol acetate (TPA) induced ear edema. UV irradiation of nifedipine and nisoldipine (which destroys the slow caicium-channel-blocking activity of these compounds) did not result in a loss of PLA₂ inhibitory activity. In fact, in both instances the UV-irradiated forms of nifedipine and nisoldipine were slightly more potent PLA₂ inhibitors than the parent compound alone. We therefore conclude that the ability of nifedipine and nisoldipine to inhibit PLA₂ was direct and unrelated to their actions on slow calcium channels.